This article is for premium subscribers!
To read further, please sign up for a premium subscription. You can also read more about standard and premium subscriptions here. Your subscription dollars are tax deductible and support the in-depth stories you appreciate from The Lund Report. If you believe you already are a premium subscriber, you are already logged in, and you are getting this message, please contact [email protected] Thanks!
If you are a premium subscriber that is not logged in, please login now.
Oregon lawmakers are considering changes to the state’s drug transparency law that would prevent pharmaceutical manufacturers from exploiting a potential loophole to avoid reporting price hikes and give state regulators more authority to expect timely information from drug companies.